Japanese pharma major Astellas (TYO: 4503) is to pay up to $102.5 million in upfront and milestone payments to acquire Seattle-based biotech Universal Cells.
The deal gives Astellas full access to the Universal Donor Cell technology for the creation of cell therapy products that do not require human leukocyte antigen (HLA) matching, potentially overcoming a huge treatment challenge by reducing the risk of rejection.
"This additional capability will further enable Astellas to develop potential innovative cell therapies"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze